Copper complexes suppress stemness, reverse epithelial‐to‐mesenchymal transition progression, and induce apoptosis on triple negative breast cancer
- 15 February 2023
- journal article
- research article
- Published by Wiley in Applied Organometallic Chemistry
- Vol. 37 (4)
Abstract
Cancer stem cells (CSCs) are a small proportion of tumor cells with great tumorigenicity, self‐renewal ability, and intrinsic resistance to conventional and targeted cancer therapy; thus, targeting CSC is becoming an emerging cancer treatment. In this paper, five novel copper (II) complexes [Cu(OH‐PIP)(Tyr)(H2O)]PF6 (1), [Cu(m‐OH‐PIP)(Gly)]NO3·2.25H2O (2), [Cu(Cl‐PIP)(Gly)Br] (3), [Cu(F‐PIP)(Tyr)Cl] (4), and [Cu(F‐PIP)(Phe)Br] (5) have been synthesized and characterized by infrared spectroscopy and single crystal X‐ray diffraction analysis. All the complexes were screened for their in vitro cytotoxicity activity against a panel of human breast cancer cells (CAL‐51, MDA‐MB‐231, and MCF‐7), human liver cancer cells (HepG 2, SMMC‐7721) and human pancreatic cancer cells (PANC‐1) using MTT assay. They have potential proliferative inhibition for all the tested cancer cell lines, especially the triple‐negative breast cancer (TNBC) CAL‐51 cells are inhibited significantly with IC50 values ranging from 0.11 to 2.35 μM. Cellular functional assays showed that representative complexes 1 and 5 could trigger apoptosis, evidenced by Hoechst 33258 staining, flow cytometry assays, and the alteration of Bax, Bcl‐2, Caspase‐3, and PARP levels. In addition, they dramatically suppressed colony and mammosphere formation, inhibited cancer cell stemness and migration, and reversed epithelial–mesenchymal transition (EMT) progression in CAL‐51 cells, indicating their great potential as anti‐CSC agents for therapy of TNBC.Keywords
Funding Information
- National Natural Science Foundation of China (21501134)
This publication has 29 references indexed in Scilit:
- Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysisAnnals of Oncology, 2018
- Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapiesCancer Treatment Reviews, 2018
- A Copper(II) Phenanthroline Metallopeptide That Targets and Disrupts Mitochondrial Function in Breast Cancer Stem CellsAngewandte Chemie International Edition, 2017
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA MutationNew England Journal of Medicine, 2017
- Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancerBreast Cancer Research and Treatment, 2017
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 StudyJournal of Clinical Oncology, 2016
- Synthesis and biological evaluation of novel aniline-derived asiatic acid derivatives as potential anticancer agentsEuropean Journal of Medicinal Chemistry, 2014
- Advances in Copper Complexes as Anticancer AgentsChemical Reviews, 2013
- Metastatic Triple-negative Breast CancerClinical Oncology, 2011
- The cancer stem cell: premises, promises and challengesNature Medicine, 2011